anti-doping analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-07. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
=== Excess facial hair in women === The topical cream is indicated for treatment of facial hirsutism in women. It is the only topical prescription treatment that slows the growth of facial hair. In clinical studies with Vaniqa, 81% of women showed clinical improvement after twelve months of treatment. Positive results were seen after eight weeks. However, discontinuation of the cream caused regrowth of hair back to baseline levels within 8 weeks. Vaniqa treatment significantly reduces the psychological burden of facial hirsutism.
NF-kappa+B at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Sankar Ghosh (2006). Handbook of Transcription Factor NF-κB. Boca Raton: CRC. ISBN 978-0-8493-2794-0. Thomas D Gilmore. "The Rel/NF-κB Signal Transduction Pathway". Boston University. Retrieved 2007-12-02.
Industrial equipment. Fish and poultry processing machinery from Baader, Lübeck, bottle washers and pasteurizers from Krones, Flensburg, grinding machine tools from Peter Wolters, Rendsburg, machinery to manufacture human-made fibers, and non-woven textile from Oerlikon Neumag and Oerlikon Nonwoven, Neumünster. Medical and labor equipment. Drägerwerk in Lübeck manufactures breathing equipment, medical ventilators and monitors, anesthetic machines, neonatal incubators, gas detectors, drug testing equipment, diving equipment, rebreathers, and breathalyzers. The company delivers breathing devices for reanimation COVID-19 patients. Euroimmun, Lübeck, produces test systems with which antibodies can be determined in the serum of patients and thus autoimmune and infectious diseases (including COVID-19) as well as allergies. Chemical. Almost all chemical industry is concentrated around Brunsbüttel. Covestro, with 650 employees, produced annually 400,000 tonnes methylene diphenyl diisocyanate, which using in synthesis of polyurethane. Yara (214 employees) produces nitrogen fertilizers, but, with a special process, instead of using natural gas, it uses heavy oil, which also allows the manufacture of byproduct vanadium oxide and sulphur. Heavy oil is a source material to produce bitumen by Total Bitumen (130 empl.). Other plant is Sasol (520 empl.), which produce fatty and Guerbet alcohols, paraffin and high-purity aluminium oxide, aluminium hydroxide and triethylaluminium.
== Disadvantages == Handling of small quantities is not always simple. Higher accuracy of weighing is necessary (e.g. use of accurate balance). Sample surface preparation can have a major impact on measurement results.
==== Fugu as a food ==== Poisoning from tetrodotoxin is of particular public health concern in Japan, where fugu is a traditional delicacy. It is prepared and sold in special restaurants where trained and licensed chefs carefully remove the viscera to reduce the danger of poisoning. There is potential for misidentification and mislabelling, particularly of prepared, frozen fish products.
Sources: en.wikipedia.org
=== 19 May === The SAF retook Wadi al-Atrun in Al-Malha, located on a strategic road linking Northern State and North Darfur. The SAF also retook Al-Salha in Omdurman, Al Alqa in the White Nile, and the Um Libana area in West Kordofan. General al-Burhan appointed Kamil Idris as prime minister.
=== Wound healing === Vascularization is crucial for wound healing, as it provides oxygen and nutrients necessary for tissue repair. Angiogenesis temporarily increases vascular density around the wound, aiding the healing process. Vascular endothelial growth factor (VEGF) is a key pro-angiogenic factor in this process, stimulating both vasculogenesis and angiogenesis in the skin. Impaired angiogenesis can result in delayed wound healing, as seen in conditions such as diabetes, where chronic wounds often exhibit reduced levels of active VEGF. Therapeutic stimulation of angiogenesis is being explored to speed up healing, especially in persistent wounds.
BeaverTails pastry (or Queues de Castor pâtisserie in Quebec) is a chain of pastry stands operated by BeaverTails Canada Inc. The chain's namesake product is a line of fried dough pastries, individually hand-stretched to resemble a beaver's tail. The chain began in Ottawa and now has franchises and licensees in six countries: Canada (Atlantic Canada, Ontario, Alberta, Manitoba, British Columbia and Quebec), the United States, Japan, France, U.A.E., and Mexico.
In the early 19th century, the British sought to reform the settlers, threatening to suspend the Public Meeting unless it observed the government's instructions to eliminate slavery outright. After a generation of wrangling, slavery was abolished in the British Empire in 1833. As a result of their enslaved Africans' abilities in the work of mahogany extraction, owners in British Honduras were compensated £53.34 per enslaved African on average (equivalent to £5,100 in 2025), the highest amount paid in any British territory. The end of slavery did little to change the formerly enslaved Africans' working conditions if they stayed at their trade. A series of institutions restricted the ability of emancipated African individuals to buy land, in a debt-peonage system. Former "extra special" mahogany or logwood cutters undergirded the early ascription of the capacities (and consequently the limitations) of people of African descent in the colony. Because a small elite controlled the settlement's land and commerce, formerly enslaved Africans had little choice but to continue to work in timber cutting. In 1836, after the emancipation of Central America from Spanish rule, the British claimed the right to administer the region. In 1862, the United Kingdom formally declared it a British Crown Colony, subordinate to Jamaica, and named it British Honduras. Since 1854, the richest inhabitants elected an assembly of notables by censal vote, which was replaced by a legislative council appointed by the British government. As a colony, Belize began to attract British investors.
Birch wood is a type of wood of the birch. Birch wood is pale yellow-brown wood having a close, straight grain and uniform texture that finishes to a smooth surface. Sometimes it is dyed to imitate mahogany. This type of wood is used for among others firewood, turnery, furniture, cabinetry, tool handles, hoops, plywood, flooring and shoe heels.
Sources: en.wikipedia.org
a Rho GTPase, usually Rac1 or Rac2 (Rac stands for Rho-related C3 botulinum toxin substrate) Five phagocytic oxidase subunits: gp91phox (NOX2) p22phox (CYBA) p40phox (NCF4) p47phox (NCF1) p67phox (NCF2)
The Transitional National Government (TNG) was established in April–May 2000 at the Somalia National Peace Conference (SNPC) held in Arta, Djibouti. Abdiqasim Salad Hassan was selected as the President of the nation's new Transitional National Government (TNG), an interim administration formed to guide Somalia to its third permanent republican government. The TNG's internal problems led to the replacement of the Prime Minister four times in three years, and the administrative body's reported bankruptcy in December 2003. Its mandate ended at the same time. On 10 October 2004, legislators elected Abdullahi Yusuf Ahmed as the first President of the Transitional Federal Government (TFG), the Transitional National Government's successor. The TFG was the second interim administration aiming to restore national institutions to Somalia after the 1991 collapse of the Siad Barre regime and the ensuing civil war. In 2006, the Islamic Courts Union (ICU) assumed control of much of the southern part of the country for 6 months and imposed Shari'a law. Top UN officials have referred to this brief period as a 'Golden era' in the history of Somali politics.
=== International activities === Since 2021 when its restaurants in China closed, White Castle does not currently have any restaurants outside of the continental United States. Through franchise deals with local corporate business partners, White Castle briefly had restaurants outside of the United States in Singapore, Malaysia, and Japan during the late 1980s and early 1990s, but the concept never caught on in those countries. During the same time period, White Castle also tried to establish franchised operations in Mexico and South Korea, but these restaurants also failed. The lone Korean restaurant in Seoul was quietly closed by 1993. In 1986, White Castle opened its first Japanese restaurant in the city of Osaka via a franchise deal with a Japanese company. There are no reliable records that show when this location closed. By the end of 1986, the Japanese franchise had six restaurants with a seventh opened by the following year. In June 1989, White Castle and its local franchise partner Innovest Bhd. opened seven restaurants in Malaysia. Innovest franchise territory included Malaysia and Singapore, and the company had plans to open three more restaurants by the end of the year, with the possibility of having a total of 20 restaurants within its two country region by the following year. The first White Castle franchised location in Mexico opened in Mexico City in 1996, but it also closed after a brief trial run. In 2017, White Castle opened its first and second restaurants in China in the city of Shanghai through a partnership with Shanghai-based ClearVue Partners.
Self-amplifying mRNA (saRNA) vaccines replicate their mRNA after transfection. Self-amplifying mRNA has two open reading frames. The first frame, like conventional mRNA, codes for the antigen of interest. The second frame codes for an RNA-dependent RNA polymerase (and its helper proteins) which replicates the mRNA construct in the cell. This allows smaller vaccine doses. The mechanisms and consequently the evaluation of self-amplifying mRNA may be different, as self-amplifying mRNA is a much bigger molecule. SaRNA vaccines being researched include a malaria vaccine. The first saRNA Covid vaccine authorised was Gemcovac, in India in June 2022. The second was ARCT-154, developed by Arcturus Therapeutics. A version manufactured by Meiji Seika Pharma was authorised in Japan in November 2023. GSK began a phase 1 trial of an saRNA COVID-19 vaccine in 2021. Gritstone bio started also started a phase 1 trial of an saRNA COVID-19 vaccine in 2021, used as a booster vaccine, with interim results published in 2023. The vaccine is designed to target both the spike protein of the SARS‑CoV‑2 virus, and viral proteins that may be less prone to genetic variation, to provide greater protection against SARS‑CoV‑2 variants. saRNA vaccines must use uridine, which is required for reproduction to occur.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.